Medscape Conference Coverage, based on selected sessions at the:

14th European Cancer Conference (ECCO 14)

September 23 - 27, 2007; Barcelona, Spain

This activity is not sanctioned by, nor a part of, the European Cancer Conference.

Conference News

  • Drug With New Mechanism of Action Shows Efficacy in Melanoma

    An experimental drug with a novel mechanism of action, the oxidative stress inducer STA-4783 has shown impressive activity in a phase 2 clinical trial in melanoma, and a larger trial is now planned.
  • Ultrasound-Guided Biopsy Reduces Surgery for Melanoma

    To avoid unnecessary surgery, melanoma patients should be routinely offered ultrasound-guided fine-needle biopsy of the lymph nodes to see whether the cancer has spread, says a German group reporting a large study.
  • Irinotecan and Cisplatin Show Rapid Response in Child Brain Gliomas

    The best responses seen to date in childhood brain gliomas have been reported by a Spanish group using a combination of cisplatin with irinotecan.
  • KRAS Mutation Predicts Lack of Response to EGFR Inhibitors

    The finding that colorectal cancer patients who do not respond to panitumumab or cetuximab have tumors with KRAS mutations is a practice-changing finding, say experts. It will allow these expensive drugs to be targeted to patients without KRAS mutations who are likely to respond.
  • Acupuncture Does Not Reduce Radiotherapy-Induced Nausea

    Genuine acupuncture was no better than sham acupuncture at reducing radiation-induced nausea in patients with various types of cancers, even though patients in both groups were convinced they were benefiting.
  • ZD4054 Improves Survival in Hormone-Refractory Prostate Cancer

    The experimental drug ZD4054 improved overall survival compared with placebo in a phase 2 trial in hormone-refractory prostate cancer, and large-scale phase 3 trials are now planned.
  • BRCA1 Expression May Guide Chemotherapy for NSCLC

    Spanish research suggests that non–small-cell lung cancer patients with high expression of BRCA1 will not benefit from platinum-based chemotherapy and should be treated with taxanes instead.
  • Detection of Circulating Tumor Cells May Guide Further Chemotherapy

    Breast cancer patients who continue to have circulating tumor cells after chemotherapy may be more likely to develop metastases and so may warrant repeat and aggressive chemotherapy, a German study suggests.
  • Trabectedin Is "Important New Option" for Advanced Sarcomas

    Just approved in Europe for use in advanced sarcoma patients who have failed first-line chemotherapy, trabectedin has been welcomed by experts as an important new option that meets a significant unmet medical need.

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the European Cancer Conference. These materials and the related activity are not sanctioned by the European Cancer Conference or the commercial supporter of the conference and do not constitute an official part of that conference.